Regulation - Actelion

Filter

Current filters:

Actelion

Popular Filters

Actelion’s Opsumit approved by SwissMedic for PAH patients

Actelion’s Opsumit approved by SwissMedic for PAH patients

14-02-2014

Swiss biotech firm Actelion announced today that SwissMedic has approved Opsumit (macitentan) for pulmonary…

ActelionBiotechnologyCardio-vascularNorthern EuropeOpsumitRegulation

Actelion gains approval in Australia for Opsumit in PAH

Actelion gains approval in Australia for Opsumit in PAH

07-02-2014

Swiss biotech firm Actelion (SIX: ATLN) has received approval of Opsumit (macitentan) for the treatment…

ActelionAustraliaBiotechnologyCardio-vascularOpsumitRegulation

Actelion’s PAH drug Opsumit approved in EU

Actelion’s PAH drug Opsumit approved in EU

22-12-2013

Switzerland-based Actelion has received European Commission approval for Opsumit (macitentan), a novel…

ActelionBiotechnologyEuropeOpsumitRegulationRespiratory and Pulmonary

Actelion receives Health Canada approval of Opsumit for PAH

Actelion receives Health Canada approval of Opsumit for PAH

13-11-2013

Swiss biotech firm Actelion (SIX: ATLN) says that Canada’s regulator Health Canada has approved its…

ActelionCanadaCardio-vascularNorth AmericaOpsumitPharmaceuticalRegulation

Positive EMA/CHMP opinions for Actelion and Lundbeck

Positive EMA/CHMP opinions for Actelion and Lundbeck

27-10-2013

At its October month-end meeting, the European Medicines Agency’s Committee for Medicinal Products…

ActelionBiotechnologyBrintellixEuropeLundbeckNeurologicalOpsumitPharmaceuticalRegulationRespiratory and Pulmonary

US FDA gives nod to Actelion’s PAH drug Opsumit

US FDA gives nod to Actelion’s PAH drug Opsumit

21-10-2013

The US Food and Drug Administration has approved Actelion's pulmonary arterial hypertension drug Opsumit…

ActelionBiotechnologyCardio-vascularNorth AmericaOpsumitRegulation

Actelion bid for Ceptaris looks secured as FDA approves Valchlor

26-08-2013

Privately-held USA-based Ceptaris Therapeutics revealed yesterday (August 26) that the US Food and Drug…

ActelionBiotechnologyCeptaris TherapeuticsDermatologicalsMergers & AcquisitionsNorth AmericaRegulationValchlor

FDA staffers back riociguat approval, but with modified dose

05-08-2013

On Tuesday (August 6), the US Food and Drug Administration's Renal Drugs Advisory Committee will discuss…

ActelionAdempasBayerNorth AmericaOpsumitPharmaceuticalRegulationRespiratory and PulmonaryriociguatTracleer

Japanese approval for Actelion's epoprostenol "ACT"

19-02-2013

Europe's largest biotech firm Actelion (SIX: ATLN) yesterday announced that Japan's Ministry of Health,…

ActelionAsia-PacificBiotechnologyepoprostenol "ACT"RegulationRespiratory and PulmonaryVeletri

Actelion filing for EU approval of Opsumit accepted

23-11-2012

Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application…

ActelionBiotechnologyEuropemacitentanOpsumitRegulationRespiratory and Pulmonary

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Actelion files for US approval of Opsumit for PAH

23-10-2012

Europe's largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug…

ActelionBiotechnologymacitentanNorth AmericaOpsumitRegulationResearchRespiratory and Pulmonary

Proposal in relation to Actelion's Tracleer in New Zealand

01-10-2012

New Zealand's national pharmaceuticals funding agency PHARMAC is seeking feedback on a proposal in relation…

ActelionAsia-PacificBiotechnologyPricingRegulationRespiratory and PulmonaryTracleer

Auxilium and Actelion get Xiaflex approval in Canada

10-07-2012

US company Auxilium Pharmaceuticals (Nasdaq: AUXL) and the Canadian subsidiary of Actelion (SIX: ATLN),…

ActelionAuxilium PharmaceuticalsBiotechnologyNorth AmericaRare diseasesRegulationXiaflex

Actelion drops setipiprant, gets miglustat approval in Japan

04-04-2012

Switzerland-based Actelion Ltd (SIX: ATLN) announced says that it will re-direct its development efforts…

ActelionAsia-PacificBiotechnologyBrazavesInflammatory diseasesMiglustatRare diseasesRegulationResearchsetipiprantZavesca

Company Spotlight

ImmunoGen

ImmunoGen

Back to top